NO. 3861 P. 126

CASE D0072 NP

## REMARKS

## AMENDMENTS TO THE SPECIFICATION

The Example section beginning on page 371, line 5 and continuing to page 506 of the substitute specification, submitted with Applicants January 5, 2005 Reply, was amended to correct typographical errors in the numbering of the Examples. Specifically, the numbering of all of the Examples residing subsequent to Example 9 was corrected to be in correct numerical order beginning with changing "Example 6" to "Example 10" and continuing to the end of the substitute specification. No new matter has been added.

NO. 3861 P. 127 CASE D0072 NP

If any small matter should remain outstanding after the Patent Examiner has had an opportunity to review the above Remarks, the Patent Examiner is respectfully requested to telephone the undersigned attorney in order to resolve these matters.

Although it is believed no fee is due, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment associated with the filing of this correspondence to Deposit Account Number 19-3880 in the name of the Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 609-252-3575

Date: June 7, 2005

Stephen C. D'Amico Agent for Applicants Reg. No. 46,652